Salarius Pharmaceuticals, Inc.
SLRX
$0.84
-$0.02-2.03%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 8.80% | 43.97% | -16.78% | -50.59% | 31.75% |
| Total Depreciation and Amortization | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1.72% | -30.75% | -34.31% | -15.00% | -29.58% |
| Change in Net Operating Assets | -1,218.09% | -85.54% | -26.31% | 250.17% | -267.56% |
| Cash from Operations | -90.97% | 27.03% | -59.15% | 45.27% | -26.53% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | -2.37% | -2.43% | -53.08% | 40.21% |
| Issuance of Common Stock | -- | -- | -- | -100.00% | 1,520.97% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 4,251.20% | -125.88% | 609.91% | -107.82% | 4,950.71% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 500.08% | -57.76% | 25.12% | -7,684.82% | 101.02% |